Status:
RECRUITING
Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer
Lead Sponsor:
Sydney Children's Hospitals Network
Collaborating Sponsors:
Children's Cancer Institute Australia
Conditions:
Neoplastic Syndromes, Hereditary
Cancer
Eligibility:
All Genders
Up to 21 years
Brief Summary
Assessment of the utility of family-based (trio) whole-genome sequencing for cancer predisposition testing in sequential newly diagnosed paediatric and adolescent cancer patients
Detailed Description
Cancer Predisposition Syndromes (CPS), caused by germline mutations in cancer predisposition genes (CPG) are heritable disorders associated with an increased risk of developing certain types of cancer...
Eligibility Criteria
Inclusion
- New diagnosis of malignancy
- Age ≤ 21 years
- Written informed consent
- Psychosocial component:
- Participants (≥ 12 years)
- Parent/caregiver(s) of participants
- Healthcare professionals involved in the care of patients enrolled in the study
Exclusion
Key Trial Info
Start Date :
March 8 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 15 2028
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT04903782
Start Date
March 8 2021
End Date
June 15 2028
Last Update
November 4 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
John Hunter Children's Hospital
Newcastle, New South Wales, Australia, 2305
2
Sydney Children's Hospital
Sydney, New South Wales, Australia, 2031
3
The Children's Hospital at Westmead
Sydney, New South Wales, Australia, 2145